CommercialPrior AuthHigh impact
Varicose Veins (CPB 0050, reviewed 2026-08-03)
Aetna·Vascular Surgery, General Surgery, Dermatology·Medical Policy
Effective date
Aug 3, 2026
We identified it
Aug 12, 2026
Summary
Aetna has updated its Clinical Policy Bulletin 0050 for varicose vein treatment, effective immediately. The policy clarifies medical necessity criteria for multiple treatment modalities including endovenous ablation, sclerotherapy, phlebectomy, and perforator vein procedures, with specific ultrasound documentation requirements and symptom thresholds. Billing teams must ensure prior authorization requests include required ultrasound findings (reflux duration ≥500ms, vein diameter measurements) and documentation of conservative management trials where applicable.
Action Required
By August 3, 2026: Billing team must implement the following immediate changes: (1) Update prior authorization templates and processes to require documentation of Doppler/duplex ultrasound performed within 6 months showing junctional reflux duration ≥500ms and vein diameter ≥4.5mm (or ≥2.5mm for sclerotherapy/phlebectomy) for all varicose vein treatment requests; (2) Create workflow checklist ensuring providers document: saphenofemoral or saphenopopliteal junction incompetence, specific vein measurements, and symptoms (ulceration, hemorrhage, or persistent pain/swelling/thrombophlebitis after 3-month conservative management trial with ≥20mmHg compression stockings); (3) Flag claims lacking this documentation for denial or return to provider; (4) Train all billing staff and clinical coders on distinction between medically necessary treatments (endovenous ablation, sclerotherapy, phlebectomy of saphenous/accessory/perforating veins meeting criteria) versus experimental/cosmetic indications (tributary veins, accessory veins other than saphenous); (5) Update claims submission software to require prior authorization for all listed procedures; (6) Communicate to providers that claims submitted without required ultrasound documentation and symptom validation will be denied. Critical note: Conservative management trial waiver applies only to patients with prior endovenous ablation or stripping in same leg.